Two lots of the same compound from the same manufacturer are not interchangeable, and the differences between them are normal rather than defective. Synthesis is a batch process. Each run has its own yield, its own impurity profile and its own counter-ion load, and the certificate exists precisely because those things differ. A result that shifts when the lot changes is one of the most common and least suspected sources of irreproducibility.
What varies and what does not
| Attribute | Varies between lots? | Why |
|---|---|---|
| Sequence | No | Fixed by the synthesis programme |
| Molecular weight | No | Follows from the sequence |
| Purity | Yes, modestly | Different yield, different cut on purification |
| Impurity profile | Yes, sometimes substantially | Which coupling fell short differs per run |
| Net peptide content | Yes, and this is the big one | Counter-ion and residual water both drift |
| Residual water | Yes | Drying cycle and subsequent handling |
The top two rows are why a lot change is usually safe. The bottom four are why it is not automatic. Identity does not drift — a correct mass is a correct mass in any batch — but almost everything quantitative does.
Which variation actually affects a result?
Net peptide content, by a wide margin. It is the fraction of the powder that is peptide, it routinely sits anywhere between about 70% and 90%, and nothing about the vial announces it. Two nominally identical stocks prepared from lots at 78% and 86% differ by roughly 10% in the only quantity the experiment is sensitive to.
A 10% shift in concentration is more than enough to move a dose–response curve visibly along its axis while leaving the shape intact, which is exactly the signature that gets attributed to biology.
How much purity variation is normal?
Within a point or two for a well-controlled process on a routine sequence. The impurity profile can move more than the headline figure: two lots both reporting 98.5% can have quite different remaining 1.5%, because which coupling fell short differs between runs. That matters when an impurity is biologically active or when it co-elutes closely enough to be counted inconsistently.
This is a case where comparing two traces says more than comparing two numbers. Same figure, different-looking trace, is worth knowing about.
Does the counter-ion change between lots?
The identity usually does not, but the amount does. Counter-ion load scales with the number of basic residues and with how the purification ran, so the same sequence can carry different trifluoroacetate mass fractions in different batches. That is a direct contributor to the net content drift above, and it is why content is reported per lot rather than quoted once for the compound.
Bridging a lot change without losing the thread
The problem is not that lots differ; it is that a change is invisible unless someone records it. Three habits handle it.
Record the lot number with every result, not every order. An experiment traced to a purchase date cannot be traced to a batch, and the batch is the unit that varies. This is the whole reason the lot gets transcribed from the vial on arrival.
Correct for content at the vial, not downstream. Apply the content figure once when the stock is made, so every dilution inherits a true concentration rather than a nominal one. Applying it later, or remembering to mention it in the write-up, is where it gets lost.
Overlap the lots where the result matters. Run the last of the old lot and the first of the new one in the same session, on the same assay. That single comparison converts an unknown into a measured offset, and it costs one extra arm.
Which compounds drift most
Variation is not uniform across a catalogue, and the sequence predicts a good deal of it.
Counter-ion load scales with basic residues, so a peptide rich in arginine and lysine carries proportionally more salt and has more room for that proportion to move between runs. A pentadecapeptide with several basic residues therefore has a wider plausible content range than a short neutral sequence does.
Synthesis difficulty matters too. A sequence with an aggregation-prone stretch produces a different deletion profile depending on how well each run went, so a longer chain can show more impurity-profile movement than a short one even when the headline purity figure is stable. And a compound where the experiment is sensitive to receptor-level differences is one where a small content shift is most likely to show up as an apparent change in behaviour.
Does a blend vary more than a single compound?
Yes, because it has more that can move. A co-formulated vial fixes its ratio at manufacture, and that ratio is itself a measured quantity with its own tolerance, sitting on top of the per-component content figures. Two lots of the same blend can therefore differ in total peptide, in the proportion between components, or both.
It is also harder to detect. With a single compound, a content figure moving from 82% to 76% is one number to notice. With a blend, the equivalent change can be distributed across components in a way no single figure on the certificate makes obvious.
Is a lot change a real explanation for a failed replication?
It is a real candidate and an under-examined one. Independent preparations from separate lots are genuinely independent in a way that two aliquots of one stock are not, so a lot change is one of the few variables that can move a result while every recorded number stays the same.
It is not the first thing to check — volumetric error and storage history are both more common — but it belongs on the list, and it is cheap to rule out if the lot numbers were recorded.
Does the supplier change between lots too?
Sometimes, and it is rarely announced. A distributor sourcing from more than one manufacturer can ship batches of the same compound made by different processes, which widens every row in the table above — impurity profiles in particular, since those are set by the synthesis route rather than by the sequence. The manufacturer's lot number is usually the only visible clue, which is another reason to record it rather than the order date. Where the chain runs through a repackager, even that can be reissued.
Should I buy a larger lot to avoid this entirely?
For a programme that will run for months and depends on tight comparability, yes, and that is standard practice for reference material. The trade is that a larger vial opened repeatedly accumulates moisture and handling exposure, so the gain in consistency is partly offset by a loss in condition. Buying one lot and aliquoting it at the start captures most of the benefit without that cost.
What should a methods section say about the lot?
The number itself, and the content figure if the calculation used one. Those two items let a reader reconcile their material with yours, and their absence is the single commonest reason two laboratories cannot explain a difference between them.
Supplier and compound name are not enough, because they identify a product rather than a batch, and the batch is the unit that varies. A methods section naming the supplier, the compound, the lot and the net peptide content has described the material completely; one naming the first two has described the order.
Where a study spans a lot change, say where it fell. A result that shifted at the same point the material changed is a far more tractable problem when the boundary is recorded than when it has to be reconstructed from purchase dates afterwards.
How often does a lot actually change?
More often than most buyers notice, because nothing announces it. A compound in steady demand turns over its stock regularly, so successive orders months apart are frequently different batches even from the same supplier.
That is the argument for recording the lot on receipt rather than only when something looks wrong. By the time a result raises a question, the vial may be empty and the packaging discarded, and the one fact that would have made the discrepancy tractable is gone. Thirty seconds at the point of arrival is the whole cost.
The habit that makes all of this manageable is small and unglamorous: write the lot number down, correct for content once at the vial, and overlap batches where the comparison matters. None of it requires extra equipment or extra spend, and together they convert the most common invisible variable in peptide work into one that can be seen and reasoned about.
Lots differing is not a problem to be solved. It is a property of batch manufacturing, documented honestly on every certificate, and the only real failure is treating two batches as one because nothing on the outside of the vial distinguished them.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
